Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematopoietic and Vascular Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD34 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD34 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD34 Products |
| Gene Delivery | CD34 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. High-titer delivery. |
View CD34 Products |
| Benchmark Ab | Anti-CD34 (Sequence of clinical-grade clones) Recombinant positive control. Sequence Verified. |
View CD34 Products |
| Validator | CD34 siRNA Set For knockdown verification and specificity screening. |
View CD34 Products |
| Related Target A | CD38 Synergistic marker for hematopoietic stem cell (HSC) lineage differentiation and leukemia profiling. |
View CD38 Products |
| Related Target B | CD133 Co-expression marker for primitive hematopoietic progenitor cells and cancer stem cell identification. |
View CD133 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent epitope mapping (Class I, II, III epitopes) | HEK293 Expressed (Native Glycosylation) preserving post-translational modifications |
| Batch-to-batch structural variation | High Purity (>95%) and Sequence Verified by Mass Spectrometry (Theoretical MW aligned) |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD34 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD34 therapeutics is intensifying, with major players shifting focus from traditional mAbs to cell therapy applications and bispecific engagers. While historically utilized as a biomarker for hematopoietic stem cell (HSC) enrichment, the next wave of R&D is targeting CD34 as a homing and vascularization target in oncology, as well as an essential quality control marker in ex vivo gene editing and CAR-T manufacturing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cell Therapy Enrichment | Miltenyi Biotec, Orchard Therapeutics | HSC Gene Therapy, Primary Immunodeficiencies | High-purity ECD-Fc proteins for antibody validation and sorting optimization |
| Bispecific Antibodies | Academic institutions, Biotech startups | Acute Myeloid Leukemia (AML), Vascular Tumors | Dual-targeting screening requiring native glycosylation profiles |
| Diagnostic / IHC Clones | Roche (Ventana), Agilent (Dako) | Dermatofibrosarcoma Protuberans, Leukemia Subtyping | Sequence Verified antigens for highly specific epitope screening |